|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 30, 2015 ) Global Markets Direct’s, ‘Pfizer Inc. – Product Pipeline Review – 2015′, provides an overview of the Pfizer Inc.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Pfizer Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Inquire more about this Report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=385991 . (This is a premium report price at US$1500 for a single user PDF license)
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope:
• The report provides brief overview of Pfizer Inc. including business description, key information and facts, and its locations and subsidiaries
• The report reviews current pipeline of Pfizer Inc.’s human therapeutic division and enlists all their major and minor projects
• The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
• Special feature on out-licensed and partnered product portfolio
• Latest news and deals relating to the Pfizer Inc.’s pipeline products
• Latest company statement
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=385991 . (This is a premium report price at US$1500 for a single user PDF license)
Reasons to Buy:
• Identify new drug targets and therapeutic classes in the Pfizer Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding the focus areas of Pfizer Inc. and exploit collaboration and partnership opportunities
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pfizer Inc.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Explore the dormant and discontinued projects of Pfizer Inc. and identify potential opportunities in those areas
More reports on Pharmaceuticals :
Global Diabetic Retinopathy Market 2015-2019
Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease.
Complete report is available http://www.rnrmarketresearch.com/global-diabetic-retinopathy-market-2015-2019-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
